Companion Society Meetings
American Society of Cytopathology
Current Concepts in Cytopathology
Sunday, March 18, 2018, 7:30 PM – 10:30 PM
3 CME and 3 SAMs
Rana S. Hoda, MD, FIAC, CBLPath, New York, NY
Significant advances in diagnostic criteria, terminologies, molecular testing and classification & reporting have taken place for practice of thyroid, salivary gland, urinary and pulmonary cytology in recent years. These areas often pose diagnostic challenges for pathologists due to a wide range of benign and malignant neoplasms and morphological overlap with benign lesions. Expert faculty will review the 2nd Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), adequacy criteria of thyroid FNA in liquid based preparations, the global impact of The Paris System for Reporting Urinary Cytopathology (TPS), role of pulmonary cytology for molecular testing of non-small cell lung carcinomas (NSCLC) and the brand new international reporting system for salivary gland cytology, The Milan System (TMS). There will be ample opportunity for the participants to interact with the faculty after each topic and in a special Q&A interval at the end of the session. After attending these timely topics, the participants will be updated and will be enabled to improve and make the necessary changes in their practice of cytopathology.
Upon completion of this educational activity, the learner will be able to:
- Demonstrate refined skills in diagnosing thyroid, salivary gland and lung FNAs and urinary cytology based on updated and newer categorization & reporting systems.
- Recognize the role and advancements in molecular testing for salivary gland and lung FNAs and urinary cytology.
- Understand the basis for adequacy criteria for thyroid FNA in The Bethesda System and how these criteria apply to liquid based cytology.
|7:40 PM||The Revised Bethesda System for Reporting Thyroid Cytopathology
Edmund S. Cibas, MD, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA
|8:10 PM||Adequacy Criteria for Thyroid FNA in Liquid Based Preparations
Jeffrey F. Krane, MD, PhD, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA
|8:30 PM||The Paris System for Reporting Urinary Cytology
Ashish Chandra, MD, FRCPath, DipRCPath, Guy’s and St. Thomas Hospital NHS, Foundation Trust, London
|9:00 PM||Current Concepts in Lung Cancer
Natasha Rekhtman, MD, Memorial Sloan Kettering Cancer Center
|9:30 PM||What’s new in salivary gland FNA reporting? The Milan System!
William C. Faquin, MD, PhD, Harvard Medical School and Massachusetts General Hospital, Boston, MA
Continuing Medical Education and Maintenance of Certification
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The United States and Canadian Academy of Pathology and American Society of Cytopathology. The United States and Canadian Academy of Pathology is accredited by the ACCME to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this live activity for a maximum of
3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Physicians must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 3 SAM credit hours.